Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hematology

Background:

• Developing effective red blood cell substitutes is crucial for oxygen delivery.
• Short circulation persistence of current substitutes limits their therapeutic potential.
• Liposome-encapsulated hemoglobin (LEH) faces challenges with rapid clearance from circulation.

Purpose of the Study:

• To enhance the circulation persistence of liposome-encapsulated hemoglobin (LEH).
• To investigate the effect of distearoyl phosphoethanolamine polyethylene glycol 5000 (PEG-PE) on LEH pharmacokinetics.
• To assess the potential of PEG-PE modified LEH as a red blood cell substitute.

Main Methods:

• Liposome-encapsulated hemoglobin (LEH) was formulated with 10 mol% distearoyl phosphoethanolamine polyethylene glycol 5000 (PEG-PE).
• PEG-LEH was radiolabeled with technetium-99m and infused into rabbits.
• Scintigraphic imaging and tissue sample analysis were used to determine circulation persistence and distribution over 48 hours.

Main Results:

• PEG-LEH demonstrated a greater than 3-fold increase in circulation half-life compared to non-PEGylated LEH.
• At 48 hours, 51.3% of the administered technetium-99m-PEG-LEH remained in circulation.
• Tissue distribution showed highest accumulation in the liver (12.7%) and bone marrow (6.2%), with minimal splenic uptake (1.4%).

Conclusions:

• The incorporation of PEG-PE into LEH formulations significantly prolongs circulation persistence.
• PEG-PE modification reduces reticuloendothelial system uptake, enhancing LEH longevity.
• This represents a substantial advancement towards developing red blood cell substitutes with sustained oxygen delivery capabilities.